Is pemetinib/dalbertam a targeted drug?

In modern tumor treatment, targeted drugs have become an indispensable and important component. The so-called "targeting" means that drugs specifically recognize and inhibit a certain type of abnormal molecules or pathways, thereby achieving more precise treatment. Pemigatinib (Pemigatinib) is just such a drug. It inhibits the signaling of FGFR family receptors to prevent the proliferation of tumor cells such as cholangiocarcinoma (CCA). Therefore, in a strict sense, pemetinib is a typical targeted drug.

Different from traditional chemotherapy, chemotherapy drugs often act directly on rapidly dividing cells and cannot distinguish between tumor cells and normal cells, so they are prone to significant side effects. Targeted drugs such as pemetinib are based on precise design at the molecular level and will only play a significant role when there are FGFR-related mutations or fusions in the patient's body. This selectivity greatly improves the pertinence of the therapeutic effect and reduces unnecessary damage.

Currently, domestic and foreign guidelines classify pemetinib as part of targeted therapy, and its status is similar to other well-known kinase inhibitors. Its emergence marks that tumor treatment is gradually moving into a more sophisticated era. Although targeted drugs are not effective for all patients, screening suitable people through molecular testing can significantly improve the efficiency of treatment. With the deepening of target research in the future, drugs like pemetinib may cover more tumor types and form an important basis for personalized treatment.

From a patient perspective, it is important to understand the positioning of pemetinib as a targeted agent. This is not only related to medication selection, but also affects communication with doctors. It is clear that it is a targeted drug, which will help patients establish reasonable treatment expectations and cooperate with the completion of genetic testing and follow-up management.

Reference materials:https://go.drugbank.com/drugs/DB15102